Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
RALEIGH, N.C., May 22, 2017 -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce that for the fourth consecutive year it was recognized as the International Clinical Research Company of the Year. PRA received the award at a PharmaTimes ceremony in London. This award follows PRA’s recent recognition as Clinical Research Company of the Year in the PharmaTimes Americas competition.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/29ac9b83-70bf-451e-a05f-bda1b8a05df8
“PRA is honored to once again receive this prestigious award,” said David Passov, Senior Vice President, Project Management EAPA. “It is recognition of our talented and dedicated employees and their passion to help others through their clinical development work.”
PRA won a total of three Gold, four Silver and five Bronze awards. Individual gold award recipients include:
- Clinical Trial Administrator of the Year: James Battisti
- Project Manager of the Year: Caroline Cattelin
Organized by PharmaTimes, the annual International Clinical Researcher of the Year competition provides a unique opportunity for clinical researchers from all over the world to benchmark their competencies and skills against their peers in an international learning environment. Designed and judged by an independent steering committee of high-level industry leaders, the International Clinical Researcher of the Year has categories for clinical researchers and teams at all stages of their career.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ: PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
MEDIA INQUIRIES: Christine Rogers, Manager - Public Relations, Corporate Communications EMAIL: [email protected] PHONE: +1 919.786.8463 INVESTOR INQUIRIES: InvestorRelations.prahs.com
